Biogened S.A. (WSE:BGD)

Biogened Statistics

Total Valuation

Biogened has a market cap or net worth of PLN 46.92 million. The enterprise value is 64.84 million.

Market Cap	46.92M
Enterprise Value	64.84M

Important Dates

The last earnings date was Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	Sep 11, 2025

Share Statistics

Biogened has 2.46 million shares outstanding.

Current Share Class	2.46M
Shares Outstanding	2.46M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.09%
Float	144,714

Valuation Ratios

The trailing PE ratio is 10.15.

PE Ratio	10.15
Forward PE	n/a
PS Ratio	0.41
PB Ratio	1.05
P/TBV Ratio	1.10
P/FCF Ratio	9.15
P/OCF Ratio	3.76
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.81, with an EV/FCF ratio of 12.65.

EV / Earnings	14.03
EV / Sales	0.57
EV / EBITDA	4.81
EV / EBIT	7.12
EV / FCF	12.65

Financial Position

The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.47.

Current Ratio	1.85
Quick Ratio	1.08
Debt / Equity	0.47
Debt / EBITDA	1.56
Debt / FCF	4.10
Interest Coverage	4.13

Financial Efficiency

Return on equity (ROE) is 10.75% and return on invested capital (ROIC) is 9.68%.

Return on Equity (ROE)	10.75%
Return on Assets (ROA)	6.57%
Return on Invested Capital (ROIC)	9.68%
Return on Capital Employed (ROCE)	14.72%
Weighted Average Cost of Capital (WACC)	5.64%
Revenue Per Employee	584,835
Profits Per Employee	23,706
Employee Count	184
Asset Turnover	1.32
Inventory Turnover	1.83

Taxes

In the past 12 months, Biogened has paid 2.28 million in taxes.

Income Tax	2.28M
Effective Tax Rate	33.00%

Stock Price Statistics

The stock price has decreased by -28.73% in the last 52 weeks. The beta is 0.14, so Biogened's price volatility has been lower than the market average.

Beta (5Y)	0.14
52-Week Price Change	-28.73%
50-Day Moving Average	20.81
200-Day Moving Average	24.63
Relative Strength Index (RSI)	34.15
Average Volume (20 Days)	202

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biogened had revenue of PLN 114.04 million and earned 4.62 million in profits. Earnings per share was 1.88.

Revenue	114.04M
Gross Profit	73.04M
Operating Income	9.11M
Pretax Income	6.90M
Net Income	4.62M
EBITDA	13.49M
EBIT	9.11M
Earnings Per Share (EPS)	1.88

Balance Sheet

The company has 6.32 million in cash and 21.03 million in debt, with a net cash position of -14.70 million or -5.99 per share.

Cash & Cash Equivalents	6.32M
Total Debt	21.03M
Net Cash	-14.70M
Net Cash Per Share	-5.99
Equity (Book Value)	44.70M
Book Value Per Share	18.20
Working Capital	21.17M

Cash Flow

In the last 12 months, operating cash flow was 12.47 million and capital expenditures -7.35 million, giving a free cash flow of 5.13 million.

Operating Cash Flow	12.47M
Capital Expenditures	-7.35M
Free Cash Flow	5.13M
FCF Per Share	2.09

Margins

Gross margin is 64.05%, with operating and profit margins of 7.99% and 4.05%.

Gross Margin	64.05%
Operating Margin	7.99%
Pretax Margin	6.05%
Profit Margin	4.05%
EBITDA Margin	11.82%
EBIT Margin	7.99%
FCF Margin	4.49%

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 2.62%.

Dividend Per Share	0.50
Dividend Yield	2.62%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	26.57%
Buyback Yield	n/a
Shareholder Yield	2.62%
Earnings Yield	9.85%
FCF Yield	10.93%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5